RE:RE:RE:Bcyc are upMy understanding is that the grading system is from 1 to 4. So, grade 5 I am going to assume they are say there were 2 death without really saying it directly.
Btw, "Tumor Lysis" is when too many tumor cells die at once and basically poison the patient. So, did these 2 patients die because their tumors died of to fast?
qwerty22 wrote: Just as an example of the slipperiness of biotech sometimes. The first toxicity statement they make is this.
" In addition, and in contrast to the toxicities observed with MedImmune’s EphA2 antibody-drug conjugate (ADC) MEDI-547, Bicycle has observed no signs of coagulopathy to date."
Which makes it sound like things are pretty good.
Next statement
"Some mild and transient neutropenia was observed at 8.5mg/m2 every week, although this did not constitute a DLT. At 10mg/m2 every other week, two DLTs were observed (Grade 3 fatigue and Grade 3 pneumonitis)."
Also not too bad, sets where the MTD might be.
Final statement.
"The most common Grade 3 and above events were neutropenia, anemia and pneumonitis and there were two Grade 5 events: tumor lysis syndrome and renal failure caused by GI-related dehydration."
Quick quiz : Anybody know what a grade 5 event is?
qwerty22 wrote:
just looking at the BT5528 data. The efficacy is really nice (hopefully they get that). Some red flags in the safety data. So the market cap is up $400-$500 mil over 1and 1/2 months. I think it started with an analyst upgrade but it looks like this data has managed to keep those gains and add to them. I don't know if as people digest that safety data there won't be some negativity.